Phosphodiesterase-5 inhibitors: Raynaud's and beyond
Indian Journal of Rheumatology, 2017 Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak +3 more
doaj +3 more sources
Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]
Frontiers in Pharmacology, 2013 Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Amit K. Tiwari, Zhe-Sheng eChen
doaj +3 more sources
Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors [PDF]
PharmaceuticsBackground/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation.
Anna I. Malykhina +2 more
doaj +2 more sources
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives [PDF]
Pharmaceuticals, 2023 Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes.
Ahmed K. ElHady +3 more
doaj +2 more sources
Phosphodiesterase-5 inhibitors for erectile function rehabilitation in patients undergoing nerve sparing radical prostatectomy: a scoping review [PDF]
Revista do Colégio Brasileiro de CirurgiõesIntroduction: The aim of this study was to conduct a scoping review on the efficacy of phosphodiesterase-5 inhibitors (PDE-5Is) in rehabilitating erectile function in patients undergoing cavernous nerve sparing radical prostatectomy (NSRP).
GABRIEL CARVALHO ANDRADE GADELHA +1 more
doaj +2 more sources
Asian Journal of Andrology, 2015 The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men naοve to phosphodiesterase 5 (PDE5) inhibitor therapies.
Wen-Jun Bai +9 more
doaj +2 more sources
Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review [PDF]
Pulmonary Circulation, 2020 Pulmonary Hypertension due to left heart disease is the most common type of Pulmonary Hypertension. Morbidity and mortality significantly increase once Pulmonary Hypertension is present.
Galo M. Sanchez Palacios +2 more
doaj +2 more sources
Identifying Phosphodiesterase‐5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders [PDF]
ChemistryOpenPhosphodiesterase type 5 (PDE5) is a multidomain protein that plays a crucial role in regulating cellular cyclic guanosine monophosphate (cGMP), a key signaling molecule involved in various physiological processes.
Mohd Shahnawaz Khan +5 more
doaj +2 more sources
Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch? [PDF]
ESC Heart Failure, 2021 E. Wilson Grandin, Jeffrey J. Teuteberg
doaj +2 more sources
Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
Molecules, 2023 This study proposed a high-performance thin-layer chromatography (HPTLC) screening method to detect phosphodiesterase 5 (PDE-5) inhibitors as possible adulterant agents in various dietary supplements.
Oana Ramona Cătălina Gheorghiu +7 more
doaj +1 more source